APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurodegenerative Disease IVD

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neurodegenerative Disease IVD Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

15 April 2026180 pages

Choose your research edition.

Industry ResearchNeurodegenerative Disease IVD Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurodegenerative Disease IVD Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Neurodegenerative Disease IVD Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurodegenerative Disease IVD Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Neurodegenerative Disease IVD Market Analysis and Forecast 2026-2032225 pages · $4,950 USD

Market perspective

The global Neurodegenerative Disease IVD market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Neurodegenerative Disease IVD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurodegenerative Disease IVD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurodegenerative Disease IVD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neurodegenerative Disease IVD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neurodegenerative Disease IVD include ADx Neurosciences, Analytik Jena, Beckman Coulter, Creative Biolabs, Fujirebio, Genemedi, Medix Biochemica, Revvity and Roche Diagnostics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Neurodegenerative Disease IVD market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurodegenerative Disease IVD and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurodegenerative Disease IVD revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Neurodegenerative Disease IVD market size, projected growth trends, production technologies, key applications, and end-use industries.

Neurodegenerative Disease IVD Segment by Company

ADx Neurosciences

Analytik Jena

Beckman Coulter

Creative Biolabs

Fujirebio

Genemedi

Medix Biochemica

Revvity

Roche Diagnostics

Neurodegenerative Disease IVD Segment by Type

Protein Biomarker Detection

Nucleic Acid Biomarker Detection

Others

Neurodegenerative Disease IVD Segment by Application

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Amyotrophic Lateral Sclerosis (ALS)

Multiple System Atrophy (MSA)

Progressive Supranuclear Palsy (PSP)

Others

Neurodegenerative Disease IVD Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease IVD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease IVD and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease IVD.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Neurodegenerative Disease IVD in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurodegenerative Disease IVD industry.

Chapter 3: Detailed analysis of Neurodegenerative Disease IVD companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neurodegenerative Disease IVDrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neurodegenerative Disease IVD Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Protein Biomarker Detection Table 3. Key Players of Nucleic Acid Biomarker Detection Table 4. Key Players of Others Table 4. Global Neurodegenerative Disease IVD Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Alzheimer's Disease Table 6. Key Players of Parkinson's Disease Table 7. Key Players of Huntington's Disease Table 8. Key Players of Amyotrophic Lateral Sclerosis (ALS) Table 9. Key Players of Multiple System Atrophy (MSA) Table 10. Key Players of Progressive Supranuclear Palsy (PSP) Table 11. Key Players of Others Table 12. Global Neurodegenerative Disease IVD Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Neurodegenerative Disease IVD Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Neurodegenerative Disease IVD Market Share by Region (2021-2026) Table 15. Global Neurodegenerative Disease IVD Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Neurodegenerative Disease IVD Market Share by Region (2027-2032) Table 17. Neurodegenerative Disease IVD Industry Trends Table 18. Neurodegenerative Disease IVD Industry Drivers Table 19. Neurodegenerative Disease IVD Industry Opportunities and Challenges Table 20. Neurodegenerative Disease IVD Industry Restraints Table 21. Global Neurodegenerative Disease IVD Revenue by Company (US$ Million) & (2021-2026) Table 22. Global Neurodegenerative Disease IVD Revenue Market Share by Company (2021-2026) Table 23. Global Neurodegenerative Disease IVD Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 24. Global Neurodegenerative Disease IVD Key Company Head Office and Area Served Table 25. Global Neurodegenerative Disease IVD Company, Product Type & Application Table 26. Global Neurodegenerative Disease IVD Company Establishment Date Table 27. Global Company Market Concentration Ratio (CR5 and HHI) Table 28. Global Neurodegenerative Disease IVD by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 29. Global Neurodegenerative Disease IVD Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Neurodegenerative Disease IVD Market Size by Type (2021-2026) & (US$ Million) Table 31. Global Neurodegenerative Disease IVD Market Size by Type (2027-2032) & (US$ Million) Table 32. Global Neurodegenerative Disease IVD Revenue Market Share by Type (2021-2026) Table 33. Global Neurodegenerative Disease IVD Revenue Market Share by Type (2027-2032) Table 34. Global Neurodegenerative Disease IVD Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Neurodegenerative Disease IVD Market Size by Application (2021-2026) & (US$ Million) Table 36. Global Neurodegenerative Disease IVD Market Size by Application (2027-2032) & (US$ Million) Table 37. Global Neurodegenerative Disease IVD Revenue Market Share by Application (2021-2026) Table 38. Global Neurodegenerative Disease IVD Revenue Market Share by Application (2027-2032) Table 39. ADx Neurosciences Company Information Table 40. ADx Neurosciences Business Overview Table 41. ADx Neurosciences Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. ADx Neurosciences Neurodegenerative Disease IVD Product Portfolio Table 43. ADx Neurosciences Recent Development Table 44. Analytik Jena Company Information Table 45. Analytik Jena Business Overview Table 46. Analytik Jena Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Analytik Jena Neurodegenerative Disease IVD Product Portfolio Table 48. Analytik Jena Recent Development Table 49. Beckman Coulter Company Information Table 50. Beckman Coulter Business Overview Table 51. Beckman Coulter Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Beckman Coulter Neurodegenerative Disease IVD Product Portfolio Table 53. Beckman Coulter Recent Development Table 54. Creative Biolabs Company Information Table 55. Creative Biolabs Business Overview Table 56. Creative Biolabs Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Creative Biolabs Neurodegenerative Disease IVD Product Portfolio Table 58. Creative Biolabs Recent Development Table 59. Fujirebio Company Information Table 60. Fujirebio Business Overview Table 61. Fujirebio Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Fujirebio Neurodegenerative Disease IVD Product Portfolio Table 63. Fujirebio Recent Development Table 64. Genemedi Company Information Table 65. Genemedi Business Overview Table 66. Genemedi Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Genemedi Neurodegenerative Disease IVD Product Portfolio Table 68. Genemedi Recent Development Table 69. Medix Biochemica Company Information Table 70. Medix Biochemica Business Overview Table 71. Medix Biochemica Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Medix Biochemica Neurodegenerative Disease IVD Product Portfolio Table 73. Medix Biochemica Recent Development Table 74. Revvity Company Information Table 75. Revvity Business Overview Table 76. Revvity Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Revvity Neurodegenerative Disease IVD Product Portfolio Table 78. Revvity Recent Development Table 79. Roche Diagnostics Company Information Table 80. Roche Diagnostics Business Overview Table 81. Roche Diagnostics Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Roche Diagnostics Neurodegenerative Disease IVD Product Portfolio Table 83. Roche Diagnostics Recent Development Table 84. North America Neurodegenerative Disease IVD Market Size by Type (2021-2026) & (US$ Million) Table 85. North America Neurodegenerative Disease IVD Market Size by Type (2027-2032) & (US$ Million) Table 86. North America Neurodegenerative Disease IVD Market Size by Application (2021-2026) & (US$ Million) Table 87. North America Neurodegenerative Disease IVD Market Size by Application (2027-2032) & (US$ Million) Table 88. North America Neurodegenerative Disease IVD Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. North America Neurodegenerative Disease IVD Market Size by Country (2021-2026) Table 90. North America Neurodegenerative Disease IVD Market Size by Country (2027-2032) Table 91. Europe Neurodegenerative Disease IVD Market Size by Type (2021-2026) & (US$ Million) Table 92. Europe Neurodegenerative Disease IVD Market Size by Type (2027-2032) & (US$ Million) Table 93. Europe Neurodegenerative Disease IVD Market Size by Application (2021-2026) & (US$ Million) Table 94. Europe Neurodegenerative Disease IVD Market Size by Application (2027-2032) & (US$ Million) Table 95. Europe Neurodegenerative Disease IVD Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. Europe Neurodegenerative Disease IVD Market Size by Country (2021-2026) Table 97. Europe Neurodegenerative Disease IVD Market Size by Country (2027-2032) Table 98. China Neurodegenerative Disease IVD Market Size by Type (2021-2026) & (US$ Million) Table 99. China Neurodegenerative Disease IVD Market Size by Type (2027-2032) & (US$ Million) Table 100. China Neurodegenerative Disease IVD Market Size by Application (2021-2026) & (US$ Million) Table 101. China Neurodegenerative Disease IVD Market Size by Application (2027-2032) & (US$ Million) Table 102. Asia Neurodegenerative Disease IVD Market Size by Type (2021-2026) & (US$ Million) Table 103. Asia Neurodegenerative Disease IVD Market Size by Type (2027-2032) & (US$ Million) Table 104. Asia Neurodegenerative Disease IVD Market Size by Application (2021-2026) & (US$ Million) Table 105. Asia Neurodegenerative Disease IVD Market Size by Application (2027-2032) & (US$ Million) Table 106. Asia Neurodegenerative Disease IVD Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Asia Neurodegenerative Disease IVD Market Size by Country (2021-2026) Table 108. Asia Neurodegenerative Disease IVD Market Size by Country (2027-2032) Table 109. South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Type (2021-2026) & (US$ Million) Table 110. South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Type (2027-2032) & (US$ Million) Table 111. South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Application (2021-2026) & (US$ Million) Table 112. South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Application (2027-2032) & (US$ Million) Table 113. South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Country (2021-2026) Table 115. South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Country (2027-2032) Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Neurodegenerative Disease IVD Product Image Figure 2. Global Neurodegenerative Disease IVD Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Neurodegenerative Disease IVD Market Share by Type: 2025 VS 2032 Figure 4. Protein Biomarker Detection Image Figure 5. Nucleic Acid Biomarker Detection Image Figure 6. Others Image Figure 7. Global Neurodegenerative Disease IVD Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Neurodegenerative Disease IVD Market Share by Application: 2025 VS 2032 Figure 9. Alzheimer's Disease Image Figure 10. Parkinson's Disease Image Figure 11. Huntington's Disease Image Figure 12. Amyotrophic Lateral Sclerosis (ALS) Image Figure 13. Multiple System Atrophy (MSA) Image Figure 14. Progressive Supranuclear Palsy (PSP) Image Figure 15. Others Image Figure 16. Global Neurodegenerative Disease IVD Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 18. Global Neurodegenerative Disease IVD Market Share by Region: 2025 VS 2032 Figure 19. Years Considered Figure 20. Global Neurodegenerative Disease IVD Market Share by Players in 2025 Figure 21. Global Top 5 and 10 Neurodegenerative Disease IVD Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Neurodegenerative Disease IVD Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Neurodegenerative Disease IVD Revenue Market Share by Type (2021-2032) Figure 25. Global Neurodegenerative Disease IVD Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Neurodegenerative Disease IVD Revenue Market Share by Application (2021-2032) Figure 27. North America Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 28. North America Neurodegenerative Disease IVD Market Share by Type (2021-2032) Figure 29. North America Neurodegenerative Disease IVD Market Share by Application (2021-2032) Figure 30. North America Neurodegenerative Disease IVD Market Share by Country (2021-2032) Figure 31. United States Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 32. Canada Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 33. Mexico Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 34. Europe Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 35. Europe Neurodegenerative Disease IVD Market Share by Type (2021-2032) Figure 36. Europe Neurodegenerative Disease IVD Market Share by Application (2021-2032) Figure 37. Europe Neurodegenerative Disease IVD Market Share by Country (2021-2032) Figure 38. Germany Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 39. France Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 40. U.K. Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 41. Italy Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 42. Russia Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 43. Nordic Countries Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 44. China Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 45. China Neurodegenerative Disease IVD Market Share by Type (2021-2032) Figure 46. China Neurodegenerative Disease IVD Market Share by Application (2021-2032) Figure 47. Asia Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 48. Asia Neurodegenerative Disease IVD Market Share by Type (2021-2032) Figure 49. Asia Neurodegenerative Disease IVD Market Share by Application (2021-2032) Figure 50. Asia Neurodegenerative Disease IVD Market Share by Country (2021-2032) Figure 51. Japan Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 52. South Korea Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 53. Taiwan Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 54. Southeast Asia Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 55. India Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 56. Australia Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 57. South America, Middle East & Africa Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 58. South America, Middle East & Africa Neurodegenerative Disease IVD Market Share by Type (2021-2032) Figure 59. South America, Middle East & Africa Neurodegenerative Disease IVD Market Share by Application (2021-2032) Figure 60. South America, Middle East & Africa Neurodegenerative Disease IVD Market Share by Country (2021-2032) Figure 61. Brazil Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 62. South Africa Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 63. Saudi Arabia Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 64. Turkey Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 65. Argentina Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 66. UAE Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 67. Egypt Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 68. Chile Neurodegenerative Disease IVD Market Size (2021-2032) & (US$ Million) Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Protein Biomarker Detection
  • Nucleic Acid Biomarker Detection
  • Others
Applications
  • Alzheimer's Disease
  • Parkinson's Disease
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Multiple System Atrophy (MSA)
  • Progressive Supranuclear Palsy (PSP)
  • Others
Companies covered
  • ADx Neurosciences
  • Analytik Jena
  • Beckman Coulter
  • Creative Biolabs
  • Fujirebio
  • Genemedi
  • Medix Biochemica
  • Revvity
  • Roche Diagnostics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Neurodegenerative Disease IVD Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Protein Biomarker Detection
  5. 1.2.3 Nucleic Acid Biomarker Detection
  6. 1.2.4 Others
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Neurodegenerative Disease IVD Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Alzheimer's Disease
  10. 1.3.3 Parkinson's Disease
  11. 1.3.4 Huntington's Disease
  12. 1.3.5 Amyotrophic Lateral Sclerosis (ALS)
  13. 1.3.6 Multiple System Atrophy (MSA)
  14. 1.3.7 Progressive Supranuclear Palsy (PSP)
  15. 1.3.8 Others
  16. 1.4 Global Market Growth Prospects
  17. 1.5 Global Neurodegenerative Disease IVD Growth Trends by Region
  18. 1.5.1 Global Neurodegenerative Disease IVD Market Size by Region: 2021 VS 2025 VS 2032
  19. 1.5.2 Neurodegenerative Disease IVD Market Size by Region (2021-2026)
  20. 1.5.3 Neurodegenerative Disease IVD Market Size by Region (2027-2032)
  21. 1.6 Assumptions and Limitations
  22. 1.7 Study Goals and Objectives
  23. 1.8 Years Considered
2 Global Neurodegenerative Disease IVD Market Dynamics
  1. 2.1 Neurodegenerative Disease IVD Industry Trends
  2. 2.2 Neurodegenerative Disease IVD Industry Drivers
  3. 2.3 Neurodegenerative Disease IVD Industry Opportunities and Challenges
  4. 2.4 Neurodegenerative Disease IVD Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Neurodegenerative Disease IVD Revenue by Company (2021-2026)
  2. 3.2 Global Neurodegenerative Disease IVD Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Neurodegenerative Disease IVD Key Company Head office and Area Served
  4. 3.4 Global Neurodegenerative Disease IVD Company, Product Type & Application
  5. 3.5 Global Neurodegenerative Disease IVD Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Neurodegenerative Disease IVD Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Neurodegenerative Disease IVD Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Neurodegenerative Disease IVD Tier 1, Tier 2, and Tier 3
4 Neurodegenerative Disease IVD Market by Type
  1. 4.1 Global Neurodegenerative Disease IVD Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Neurodegenerative Disease IVD Market Size by Type (2021-2032)
  3. 4.3 Global Neurodegenerative Disease IVD Market Size Share by Type (2021-2032)
5 Neurodegenerative Disease IVD Market by Application
  1. 5.1 Global Neurodegenerative Disease IVD Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Neurodegenerative Disease IVD Market Size by Application (2021-2032)
  3. 5.3 Global Neurodegenerative Disease IVD Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 ADx Neurosciences
  2. 6.1.1 ADx Neurosciences Company Information
  3. 6.1.2 ADx Neurosciences Business Overview
  4. 6.1.3 ADx Neurosciences Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 ADx Neurosciences Neurodegenerative Disease IVD Product Portfolio
  6. 6.1.5 ADx Neurosciences Recent Developments
  7. 6.2 Analytik Jena
  8. 6.2.1 Analytik Jena Company Information
  9. 6.2.2 Analytik Jena Business Overview
  10. 6.2.3 Analytik Jena Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Analytik Jena Neurodegenerative Disease IVD Product Portfolio
  12. 6.2.5 Analytik Jena Recent Developments
  13. 6.3 Beckman Coulter
  14. 6.3.1 Beckman Coulter Company Information
  15. 6.3.2 Beckman Coulter Business Overview
  16. 6.3.3 Beckman Coulter Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Beckman Coulter Neurodegenerative Disease IVD Product Portfolio
  18. 6.3.5 Beckman Coulter Recent Developments
  19. 6.4 Creative Biolabs
  20. 6.4.1 Creative Biolabs Company Information
  21. 6.4.2 Creative Biolabs Business Overview
  22. 6.4.3 Creative Biolabs Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Creative Biolabs Neurodegenerative Disease IVD Product Portfolio
  24. 6.4.5 Creative Biolabs Recent Developments
  25. 6.5 Fujirebio
  26. 6.5.1 Fujirebio Company Information
  27. 6.5.2 Fujirebio Business Overview
  28. 6.5.3 Fujirebio Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Fujirebio Neurodegenerative Disease IVD Product Portfolio
  30. 6.5.5 Fujirebio Recent Developments
  31. 6.6 Genemedi
  32. 6.6.1 Genemedi Company Information
  33. 6.6.2 Genemedi Business Overview
  34. 6.6.3 Genemedi Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Genemedi Neurodegenerative Disease IVD Product Portfolio
  36. 6.6.5 Genemedi Recent Developments
  37. 6.7 Medix Biochemica
  38. 6.7.1 Medix Biochemica Company Information
  39. 6.7.2 Medix Biochemica Business Overview
  40. 6.7.3 Medix Biochemica Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Medix Biochemica Neurodegenerative Disease IVD Product Portfolio
  42. 6.7.5 Medix Biochemica Recent Developments
  43. 6.8 Revvity
  44. 6.8.1 Revvity Company Information
  45. 6.8.2 Revvity Business Overview
  46. 6.8.3 Revvity Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Revvity Neurodegenerative Disease IVD Product Portfolio
  48. 6.8.5 Revvity Recent Developments
  49. 6.9 Roche Diagnostics
  50. 6.9.1 Roche Diagnostics Company Information
  51. 6.9.2 Roche Diagnostics Business Overview
  52. 6.9.3 Roche Diagnostics Neurodegenerative Disease IVD Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Roche Diagnostics Neurodegenerative Disease IVD Product Portfolio
  54. 6.9.5 Roche Diagnostics Recent Developments
7 North America
  1. 7.1 North America Neurodegenerative Disease IVD Market Size (2021-2032)
  2. 7.2 North America Neurodegenerative Disease IVD Market Size by Type
  3. 7.2.1 North America Neurodegenerative Disease IVD Market Size by Type (2021-2026)
  4. 7.2.2 North America Neurodegenerative Disease IVD Market Size by Type (2027-2032)
  5. 7.2.3 North America Neurodegenerative Disease IVD Market Share by Type (2021-2032)
  6. 7.3 North America Neurodegenerative Disease IVD Market Size by Application
  7. 7.3.1 North America Neurodegenerative Disease IVD Market Size by Application (2021-2026)
  8. 7.3.2 North America Neurodegenerative Disease IVD Market Size by Application (2027-2032)
  9. 7.3.3 North America Neurodegenerative Disease IVD Market Share by Application (2021-2032)
  10. 7.4 North America Neurodegenerative Disease IVD Market Size by Country
  11. 7.4.1 North America Neurodegenerative Disease IVD Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Neurodegenerative Disease IVD Market Size by Country (2021-2026)
  13. 7.4.3 North America Neurodegenerative Disease IVD Market Size by Country (2027-2032)
  14. 7.4.4 North America Neurodegenerative Disease IVD Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Neurodegenerative Disease IVD Market Size (2021-2032)
  2. 8.2 Europe Neurodegenerative Disease IVD Market Size by Type
  3. 8.2.1 Europe Neurodegenerative Disease IVD Market Size by Type (2021-2026)
  4. 8.2.2 Europe Neurodegenerative Disease IVD Market Size by Type (2027-2032)
  5. 8.2.3 Europe Neurodegenerative Disease IVD Market Share by Type (2021-2032)
  6. 8.3 Europe Neurodegenerative Disease IVD Market Size by Application
  7. 8.3.1 Europe Neurodegenerative Disease IVD Market Size by Application (2021-2026)
  8. 8.3.2 Europe Neurodegenerative Disease IVD Market Size by Application (2027-2032)
  9. 8.3.3 Europe Neurodegenerative Disease IVD Market Share by Application (2021-2032)
  10. 8.4 Europe Neurodegenerative Disease IVD Market Size by Country
  11. 8.4.1 Europe Neurodegenerative Disease IVD Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Neurodegenerative Disease IVD Market Size by Country (2021-2026)
  13. 8.4.3 Europe Neurodegenerative Disease IVD Market Size by Country (2027-2032)
  14. 8.4.4 Europe Neurodegenerative Disease IVD Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Neurodegenerative Disease IVD Market Size (2021-2032)
  2. 9.2 China Neurodegenerative Disease IVD Market Size by Type
  3. 9.2.1 China Neurodegenerative Disease IVD Market Size by Type (2021-2026)
  4. 9.2.2 China Neurodegenerative Disease IVD Market Size by Type (2027-2032)
  5. 9.2.3 China Neurodegenerative Disease IVD Market Share by Type (2021-2032)
  6. 9.3 China Neurodegenerative Disease IVD Market Size by Application
  7. 9.3.1 China Neurodegenerative Disease IVD Market Size by Application (2021-2026)
  8. 9.3.2 China Neurodegenerative Disease IVD Market Size by Application (2027-2032)
  9. 9.3.3 China Neurodegenerative Disease IVD Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Neurodegenerative Disease IVD Market Size (2021-2032)
  2. 10.2 Asia Neurodegenerative Disease IVD Market Size by Type
  3. 10.2.1 Asia Neurodegenerative Disease IVD Market Size by Type (2021-2026)
  4. 10.2.2 Asia Neurodegenerative Disease IVD Market Size by Type (2027-2032)
  5. 10.2.3 Asia Neurodegenerative Disease IVD Market Share by Type (2021-2032)
  6. 10.3 Asia Neurodegenerative Disease IVD Market Size by Application
  7. 10.3.1 Asia Neurodegenerative Disease IVD Market Size by Application (2021-2026)
  8. 10.3.2 Asia Neurodegenerative Disease IVD Market Size by Application (2027-2032)
  9. 10.3.3 Asia Neurodegenerative Disease IVD Market Share by Application (2021-2032)
  10. 10.4 Asia Neurodegenerative Disease IVD Market Size by Country
  11. 10.4.1 Asia Neurodegenerative Disease IVD Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Neurodegenerative Disease IVD Market Size by Country (2021-2026)
  13. 10.4.3 Asia Neurodegenerative Disease IVD Market Size by Country (2027-2032)
  14. 10.4.4 Asia Neurodegenerative Disease IVD Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Neurodegenerative Disease IVD Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Neurodegenerative Disease IVD Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Neurodegenerative Disease IVD Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Neurodegenerative Disease IVD Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Neurodegenerative Disease IVD Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst